United States Exocrine Pancreatic Insufficiency Treatment Market 2024-2031: Comprehensive Analysis of Pancreatic Enzyme Replacement Therapy, Nutritional Management, Emerging Therapies, and Strategic Growth Opportunities

The Global Exocrine Pancreatic Insufficiency Treatment Market reached US$ 3.30 billion in 2023 and is expected to reach US$ 5.37 billion by 2031, growing at a CAGR of 6.4% during the forecast period 2024-2031.

Exocrine Pancreatic Insufficiency (EPI) is a condition where the pancreas fails to produce sufficient digestive enzymes, leading to malabsorption, nutrient deficiencies, and gastrointestinal issues. Treatments primarily involve pancreatic enzyme replacement therapy (PERT), dietary modifications, and adjunctive nutritional supplements. The market is expanding due to increasing prevalence of chronic pancreatitis, cystic fibrosis, pancreatic cancer, and growing awareness of enzyme therapy benefits.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Exocrine Pancreatic Insufficiency Treatment Market Landscape:- https://datamintelligence.com/download-sample/exocrine-pancreatic-insufficiency-treatment-market?rk

☛ Exocrine Pancreatic Insufficiency Treatment Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In August 2025, Abbott Laboratories expanded its pancreatic enzyme replacement therapy (PERT) portfolio in the U.S., providing improved formulations for EPI patients.

✅ In July 2025, Nestlé Health Science launched next-generation oral enzyme therapies targeting better digestion and nutrient absorption in EPI patients.

✅ In June 2025, Viatris partnered with U.S. gastroenterology centers to deploy innovative PERT formulations, enhancing patient adherence and quality of life.

Europe: Recent Industry Developments

✅ In July 2025, Ipsen Pharma introduced advanced enzyme replacement therapies for EPI management across EU hospitals, supporting improved gastrointestinal function.

✅ In June 2025, Abbott Europe expanded its PERT solutions, integrating patient-friendly dosing and extended-release formulations for better therapeutic outcomes.

✅ In May 2025, Nestlé Health Science Europe partnered with European clinics to implement optimized EPI treatment protocols, enhancing patient satisfaction and nutrition management.

Japan: Recent Industry Developments

✅ In July 2025, Kowa Company launched next-generation pancreatic enzyme therapies for EPI patients in Japan, focusing on digestion improvement and nutritional support.

✅ In June 2025, EA Pharma Co., Ltd. expanded its PERT product line, supporting better absorption and adherence in Japanese patients.

✅ In May 2025, Abbott Japan partnered with gastroenterology centers to deploy innovative enzyme replacement therapies, improving patient outcomes and care efficiency.

☛ Exocrine Pancreatic Insufficiency Treatment Market Trends:

Therapeutic Advancements: Innovations in high-potency enzyme formulations, enteric-coated capsules, and personalized dosing strategies are improving digestion efficiency, patient compliance, and quality of life.

Rising Disease Awareness: Increasing recognition of EPI symptoms among healthcare providers and patients is driving early diagnosis and treatment adoption.

Market Segmentation: Pancreatic enzyme replacement therapy dominates, while nutritional supplements and adjunct therapies are gaining traction for comprehensive management.

Regional Insights: North America and Europe lead the market due to advanced healthcare infrastructure, high diagnosis rates, and availability of specialized enzyme therapies. Asia-Pacific is growing rapidly, driven by improving healthcare access, rising chronic pancreatitis cases, and increased awareness of EPI treatment options.

Challenges: High treatment costs, limited awareness in developing regions, and the need for lifelong therapy may restrain growth.

Strategic Initiatives: Companies are focusing on R&D for more effective enzyme formulations, personalized treatment regimens, and partnerships with healthcare providers to enhance adoption and patient outcomes.

☛ Exocrine Pancreatic Insufficiency Treatment Market Competitve Landscape:

AbbVie, Codexis Inc., Nestle, Alcresta Therapeutics, Inc., First Wave BioPharma, Eli Lilly and Company, Cilian AG, Synspira Therapeutics, Perseo Pharma, and Vivus LLC.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/exocrine-pancreatic-insufficiency-treatment-market

☛ Segment Covered in the Exocrine Pancreatic Insufficiency Treatment Market:

By Treatment: Drug Type, Creon, Zenpep, Pancreaze, Ultra, Viokace, Others, Nutritional management (Dietary Supplements), Pancreatic Enzyme Replacement Therapy.

By Application: Crohn's Disease, Ulcerative Colitis, GERD, IBS, Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Exocrine Pancreatic Insufficiency Treatment Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=exocrine-pancreatic-insufficiency-treatment-market

☛ Regional Analysis for Exocrine Pancreatic Insufficiency Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ Frequently asked questions:

➠ What is the global sales, production, consumption, import, and export value of the Exocrine Pancreatic Insufficiency Treatment Market?
➠ Who are the key global manufacturers, and what is their operational performance?
➠ What are the major opportunities and threats in the global Exocrine Pancreatic Insufficiency Treatment Market?
➠ Which product types or end-users show the most growth potential and market share?
➠ What challenges and constraints are impacting the Exocrine Pancreatic Insufficiency Treatment Market?
➠ What sales, marketing, and distribution channels are used globally?

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.